Pharma Commercial Forecasting Expert — Launch Curves

$130–210/hrrate as listed

Mercor is running a paid pilot with a biotech/pharma research team to build and critique rubrics for evaluating commercial drug forecasts and development programs. You'll assess launch curves — uptake, peak share, trajectory, LOE — and judge whether a forecast's underlying assumptions hold up.

Summary, eligibility guidance and screening preparation are prepared by Sidequest from the platform's posting. Check the source listing before applying.

The work

This is expert human evaluation applied to pharma commercial models. Day to day, you'll be handed forecasts and program analyses — some model-generated, some drafted for critique — and asked to say whether they're defensible. That means constructing or dismantling launch curves: is the uptake slope consistent with the chosen analogs? Is peak share plausible given the competitive set and payer dynamics? Does the ramp reflect real-world access timelines, or does it assume formulary wins that take 18 months? Is loss-of-exclusivity treated with any seriousness, or bolted on as a cliff?

You'll also work on the rubrics themselves. Writing a rubric that distinguishes a strong commercial forecast from a superficially plausible one is harder than scoring against one, and the pilot leans on experts who can articulate why an assumption fails, in terms a reviewer without your background can apply consistently.

What the screen looks for

Specific launches you've forecast or modeled, and what you got wrong — analog selection reasoning is the core probe
Fluency with the mechanics: bass-style diffusion vs. patient-flow builds, source-of-business logic, gross-to-net, persistency assumptions
Ability to critique rather than just produce — the AI interviewer will push back on your reasoning and watch whether you hold or refine your position
Whether your experience is genuinely commercial forecasting or adjacent (sales, MSL, market access is acceptable if the launch-model exposure is real)

Logistics

Remote, US-based only. The pilot runs roughly 10–20 hours across one to two weeks, largely async — you pick up assignments and turn them around against deadlines rather than sitting in scheduled sessions. Observed pay for this listing is $130–210/hr, set by the platform and not guaranteed for any individual engagement. Strong contributors are told there's follow-on work as the program scales, though the pilot is the only committed scope.

What they look for

5+ years in pharma commercial forecasting, analytics, or strategy
Hands-on experience building or critiquing drug launch and uptake models
Working knowledge of biotech/pharma development programs and clinical-to-commercial handoff
Analog selection and peak-share estimation judgment
Ability to write and critique evaluation rubrics in clear, transferable language
US-based

Before you apply

Would you pass this screen?

Drawn from what this listing actually requires. Answered in your browser — nothing is sent to us, and we do not store your answers.

Are you currently employed in or have you worked in a pharma, biotech, or CRO role focused on commercial forecasting, market analysis, sales strategy, or launch planning in the United States?
Pharma commercial/forecasting professional based in the US · required
Do you have 5 or more years of professional experience in pharma commercial forecasting, market analytics, sales forecasting, or commercial strategy roles?
5+ years experience in pharma commercial forecasting, analytics, or strategy · required
Have you personally built or formally critiqued a drug launch forecast or uptake model (including ramp curve, peak share, LoE assumptions, or competitive positioning)?
Drug launch modeling experience · required
Are you familiar with biotech and pharma drug-development programs, including pipeline progression, clinical trial phases, regulatory pathways, and commercial readiness milestones?
Biotech/pharma development program familiarity · preferred

0 of 4 answered

Included with this listing

Interview prep — 13 questions

Matched to what this platform's screening actually measures. Answer each out loud in 60–90 seconds: claim → concrete example → implication.

What it tests: Whether the candidate has hands-on experience translating market dynamics into concrete forecast parameters (ramp rate, peak share, LoE impact), not just awareness that these matter.
A strong answer: The candidate names a specific launch (or program stage), identifies 2–3 assumption categories (analogs selected, ramp trajectory, peak timing, LoE cliff), and explains the evidence or historical precedent that anchored each—e.g., 'We benchmarked the ramp against three HbA1c agents with similar mechanisms and patient switching barriers, which gave us a 18–24 month slope.'
Where people lose it: Candidate describes a forecast they reviewed or discussed secondhand, or names assumptions without explaining why they held—'We assumed peak share of 12% because we thought the market was competitive' signals no rigor and no seat at the table in evaluation.